CGT
-
The resignation letter of FDA CBER Director Peter Marks, MD, PhD
For more reports, please follow DrugTimes
-
The “Hidden Reasons” Behind WuXi AppTec’s Sale of CGT Business
It is believed that both WuXi AppTec and WuXi ATU will continue to exert greater energy for more innovators and patients in need in the future
-
Gene editing therapy bombshell: A trial participant has died
many analysts are positive about Beam’s future
-
CGT领域外商投资准入最新趋势观察和合规要点建议
01 引言 细胞和基因治疗（Cell and Gene Therapies, “CGT”）具有广阔前景，国家层面对于推动这一领域的产业发展给予了极大的重视和支持。然而，在外商投资领…
-
中国CGT赛道的转机来了！
正文共： 1566字 19图 预计阅读时间： 4分钟 2024年9月8日，商务部官网发布“商务部 国家卫生健康委 国家药监局关于在医疗领域开展扩大开放试点工作的通知”…
-
CGT，触底反弹？
2024年，在肿瘤、自免、代谢等领域投融资/并购交易进行的如火如荼之际，CGT领域的寒冰未显露出任何消融的迹象。 据悉，截至8月8日，CGT领域共发生16 笔投融资活动，共筹集5亿…
-
Eli Lilly Pipeline Analysis: Gene Therapy Products Accounts for 1/3, What Diseases Are Targeted?
DrugTimes will present more reports on CGT. Please stay tuned
-
Stock prices soar by 220%! CGT, once “unsellable,” is back in the spotlight
If you are intersted in TCR-T, you are welcome to watch DrugTimes webinar tonight
-
19款FDA批准的基因疗法
根据2024年7月12日CBER主任Peter Marks博士的演讲和公开信息准备
-
Exchanging a CAR-T therapy for 18% of the shares, the decision-making of Innovent Biologics
All comments are highly welcome!
